Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menstrual suppression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Menstrual suppression. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-005315-26 Sponsor Protocol Number: A25165 Start Date*: 2008-07-01
    Sponsor Name:CONRAD, Eastern Virgina Medical School
    Full Title: Sperm Suppression and Contraceptive Protection provived by Norethisterone Enantate (NET-EN) combined with Testosterone Undecanoate (TU) in healthy men.
    Medical condition: The proposed study is designed to evaluate whether the combination of a progestin, norethisterone enantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effective ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Temporarily Halted) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2019-001143-43 Sponsor Protocol Number: EU-KKO-LNG-02-2018 Start Date*: 2019-10-07
    Sponsor Name:Gedeon Richter Plc.
    Full Title: An Open-label, Multi-center, Pharmacokinetic/Pharmacodynamic Study to Evaluate the Effect of a Single Dose of Levonorgestrel 1.5 mg Tablet on Ovulation Inhibition during Mid-follicular Phase in Und...
    Medical condition: Ovulation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10036251 Post coital contraception PT
    20.0 100000004860 10033313 Ovulation inhibited LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003980-62 Sponsor Protocol Number: GBG 37 Start Date*: 2005-01-13
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline ...
    Medical condition: -young hormone insensitive breast cancer patients receiving anthracycline containing (neo-)adjuvant chemotherapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003829-28 Sponsor Protocol Number: TAK-013/EC204 Start Date*: 2004-12-22
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: An open-label investigation into the tolerability and pharmacokinetic / pharmacodynamic effects of sufugolix (TAK-013), at a dosage of 100mg twice-daily, during six months treatment of pre-menopaus...
    Medical condition: symptomatic endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000899-23 Sponsor Protocol Number: CORT125134-451 Start Date*: 2016-08-16
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000230-39 Sponsor Protocol Number: FOG 2006 Start Date*: 2008-04-14
    Sponsor Name:Endocrine Society of Czech Republic
    Full Title: Protective effect of gonadoliberin analogues on endocrine and reproduction ovarian function during antitumour treatment in young girls and women in fertile period: Project of pharmacological gonada...
    Medical condition: The patient with diagnosis: Hodgkin disease and leukaemia. Patients starting at adolescence (B3 - B4 for breast development accordig Tanner criteria) till 34 years be included. ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002268-53 Sponsor Protocol Number: 219288 Start Date*: 2022-12-09
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepa...
    Medical condition: Chronic Hepatitis B infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) DE (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005139-22 Sponsor Protocol Number: 202009 Start Date*: 2022-12-09
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepa...
    Medical condition: Chronic Hepatitis B infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) DE (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002498-36 Sponsor Protocol Number: CCN017 Start Date*: 2018-10-12
    Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
    Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002600-33 Sponsor Protocol Number: IBCSG 34-05/ SWOG 0230 Start Date*: 2007-02-16
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
    Medical condition: Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000089-41 Sponsor Protocol Number: FCH-LNG-BW-01 Start Date*: 2020-05-26
    Sponsor Name:Foundation Consumer Healthcare (FCH)
    Full Title: Randomized, Open-Label, Multicenter Proof-of-Principle Study to Assess the Effect of Single Doses of 1.5 mg and 3.0 mg Levonorgestrel During the Mid-Follicular Phase on the Inhibition of Ovulation ...
    Medical condition: Inhibition of Ovulation in Women Across Body Weight Categories During the Mid-Follicular Phase
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004865 10082354 Emergency contraceptive pill LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005337-37 Sponsor Protocol Number: ONC-2012-002 Start Date*: 2013-05-07
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE
    Medical condition: Female subjects, aged <40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim to assess the role of AMH as surrogate marker of the preservation of ovarian rese...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000798-59 Sponsor Protocol Number: 0080CA001 Start Date*: 2016-08-02
    Sponsor Name:Novalon S.A
    Full Title: Phase III, open-label, multi-centre study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 3.6 mg goserelin subcutaneous implant (Novalon) in women with confirmed end...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003071-18 Sponsor Protocol Number: MK-8591-013 Start Date*: 2021-02-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed o...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2008-007337-49 Sponsor Protocol Number: CLCI699A2215 Start Date*: 2009-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized, double-blind, placebo controlled, multi-center study to evaluate the effects of LCI699 on cortisol in patients with hypertension.
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2007-002125-68 Sponsor Protocol Number: IM103-045 Start Date*: 2007-11-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients Revised Protocol Number 04, incorporating Amendments 02, 03, 04 and 05 (version 10.0 dated 20-Nov-0...
    Medical condition: First time recipient of a deceased donor liver transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024714 Liver transplant LLT
    9.1 10062016 Immunosuppression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003467-19 Sponsor Protocol Number: CLEE011A2404 Start Date*: 2016-12-08
    Sponsor Name:Novartis Pharma AG
    Full Title: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal wo...
    Medical condition: hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed) SK (Completed) IT (Completed) CZ (Completed) AT (Completed) ES (Completed) DK (Completed) NO (Completed) PL (Completed) FI (Completed) SI (Completed) RO (Ongoing) LU (Completed)
    Trial results: View results
    EudraCT Number: 2008-003183-19 Sponsor Protocol Number: CA180-261 Start Date*: 2009-02-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin®) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Pro...
    Medical condition: Advanced Estrogen Receptor-Positive Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) CZ (Completed) IT (Completed) SE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005544-17 Sponsor Protocol Number: EMR 200038-010 Start Date*: 2009-08-20
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy...
    Medical condition: post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Completed) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) SK (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002816-22 Sponsor Protocol Number: CTL-002-002 Start Date*: 2023-03-09
    Sponsor Name:Catalym GmbH
    Full Title: A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
    Medical condition: Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 02:45:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA